VS-7375 (GFH375) — FDA meeting
Late 2026
We expect to meet with the FDA before the end of 2026 to review Phase 3 pivotal trial designs in first-line ("1L") metastatic PDAC, 1L metastatic CRC, and 1L advanced NSCLCSource filing
VSTM biotech catalysts & pipeline
VERASTEM INC · Data as of 2026-09-08
Upcoming catalysts
VS-7375 (GFH375) — Topline data
October
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in OctoberSource filing
avutometinib + defactinib — Topline data
mid-2027
Expect to report topline readout of primary endpoint by mid-2027Source filing